B cell-targeted immunotherapy for type 1 diabetes: What can make it work?

Abdel Rahim A. Hamad, Rizwan Ahmed, Thomas Donner, Georgia Fousteri

Research output: Contribution to journalArticlepeer-review

Abstract

Immunotherapy has revolutionized treatment of cancers and autoimmune diseases. Bucking the trend, however, is type 1 diabetes (T1D), although it is one of best understood autoimmune diseases and individuals at genetic risk are identifiable with high certainty. Here we review the major obstacles associated with pan-B-cell-depletion using rituximab (RTX) and discuss the notion that B cell-directed therapy may be most effective as a preventive measure. We suggest that it will be more productive to aim at identifying and targeting autoreactive B cells rather than making adjustments to pan-B cell depletion and that non-conventional alternative therapies such as antibody blockade of FasL to bolster IL-10-producing Breg cells, which work successfully in mice, should be considered.
Original languageEnglish
Pages (from-to)213 - 219
Number of pages7
JournalDiscovery medicine
Volume21
Issue number115
Publication statusPublished - 2016

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'B cell-targeted immunotherapy for type 1 diabetes: What can make it work?'. Together they form a unique fingerprint.

Cite this